Cargando…

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment

BACKGROUND: Immunological contexture differs across malignancies, and understanding it in the tumor microenvironment (TME) is essential for development of new anticancer agents in order to achieve synergistic effects with anti-programmed cell death protein-1 (PD-1) therapy. TYRO3, AXL, and MERTK rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Miso, Kuen, Da-Sol, Park, Jaewoo, Choi, Munkyung, Kim, Yeonji, Roh, Eun Chae, Choi, Yong June, Kim, Yoon Gyoon, Chung, Yeonseok, Cho, Sung Yun, Kang, Keon Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884874/ https://www.ncbi.nlm.nih.gov/pubmed/36693679 http://dx.doi.org/10.1136/jitc-2022-006084

Ejemplares similares

Type 17 immunity promotes the exhaustion of CD8(+) T cells in cancer
por: Kim, Byung-Seok, et al.
Publicado: (2021)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39(+) CD8 T cells from primary and metastatic sites of epithelial ovarian cancers
por: Leem, Galam, et al.
Publicado: (2020)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
por: Martins Nascentes Melo, Luiza, et al.
Publicado: (2023)

Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
por: Park, Young-Jun, et al.
Publicado: (2018)

Gallic acid induces T-helper-1-like T(reg) cells and strengthens immune checkpoint blockade efficacy
por: Deng, Biaolong, et al.
Publicado: (2022)

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
por: Wang, Minglei, et al.
Publicado: (2023)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

Critical regulation of follicular helper T cell differentiation and function by Gα(13) signaling
por: Kuen, Da-Sol, et al.
Publicado: (2021)

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Hubert, Pascale, et al.
Publicado: (2021)

Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
por: Khan, Saad M, et al.
Publicado: (2022)

EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1
por: Park, Dong Jun, et al.
Publicado: (2020)

TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8(+) T cell and XCR1(+) dendritic cell spatial co-localization
por: Gardner, Alycia, et al.
Publicado: (2022)

THU502 CYR61, A Member Of The CCN Protein Family, Regulates IGF1 In Metastatic Prostate Cancer
por: Ortiz Hernandez, Greisha L, et al.
Publicado: (2023)

Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite
por: Renga, Giorgia, et al.
Publicado: (2022)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Regulation of tumor growth by leukocyte-specific protein 1 in T cells
por: Kwon, Riri, et al.
Publicado: (2020)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
por: Peng, Zhi-Peng, et al.
Publicado: (2023)

ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics
por: Park, Joo Dong, et al.
Publicado: (2022)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
por: McAuliffe, James, et al.
Publicado: (2021)

Genome-wide analysis of histone modifications in latently HIV-1 infected T cells
por: Park, Jihwan, et al.
Publicado: (2014)

Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
por: Church, Candice, et al.
Publicado: (2022)

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
por: Yang, Rui, et al.
Publicado: (2020)

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
por: Nam, Gi-Hoon, et al.
Publicado: (2021)

Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1
por: Cho, Seongmin, et al.
Publicado: (2020)

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
por: Lee, Eunhee, et al.
Publicado: (2023)

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
por: Kim, Chang Gon, et al.
Publicado: (2021)

Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy
por: Nagaoka, Koji, et al.
Publicado: (2020)

Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
por: Aoyama, Shota, et al.
Publicado: (2021)

Autocrine TGF-β1 Maintains the Stability of Foxp3(+) Regulatory T Cells via IL-12Rβ2 Downregulation
por: Choi, Garam, et al.
Publicado: (2020)

Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway
por: Zhuo, Yue, et al.
Publicado: (2022)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Kortekaas, Kim E, et al.
Publicado: (2021)

CCN4/WISP1 Promotes Migration of Human Primary Osteoarthritic Chondrocytes
por: Timmermans, Ritchie G.M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8i6h29eit9tauc9m5d9fu0eo09